Moderna’s Melanoma Vaccine Breakthrough | Atlanta News

Moderna’s stock surged over 100% after breakthrough melanoma vaccine results—showing promise in preventing cancer recurrence post-surgery when paired with Merck’s immunotherapy. Experts hail it as a landmark moment, bringing personalized cancer treatment closer to reality and potentially saving thousands of lives annually. While shares remain below pandemic-era highs, the future of melanoma care just got dramatically brighter. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3f6ff063dc0c83d9